TrialNeuro-oncology2011

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma.

Patrick Y Wen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.